doi: 10.1016/S2352-4642(22)00373-X 9 GriggsCLPerezNPJrGoldstoneRNKelleherCMChangDCStanfordFCet al
[4] Therefore, direct pharmacokinetic interactions between berberine and semaglutide are unlikely
The thing is, the experience of injectables is not for everyone
One subsequent analysis has estimated that 7.9 million individuals meet the SELECT trial criteria in the US: Among these individuals, treatment with semaglutide could prevent about 190 000 cardiovascular events in 5 years. If each eligible patient received semaglutide at a retail price of $16 188 per year, the total cost would amount to $127 billion per year. The authors of SELECT noted that: Potentially less costly alternatives for reducing obesity and CVD risk include lifestyle counseling, dietary fasting, and alternative pharmacological weight loss approaches
Beware Energy Drinks: A Case of a Toxic Triad Syndrome in a Diabetic Patient With Nonalcoholic Fatty Liver Disease
References: John P H Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies, Luc F Van Gaal, Ildiko Lingvay, Barbara M McGowan, Julio Rosenstock, Marie T D Tran, Thomas A Wadden, Sean Wharton, Koutaro Yokote, Niels Zeuthen, Robert F Kushner